
Navigating academia and industry to deliver ocular gene therapies
Dr Shannon E Boye, Co-Founder and Chief Scientific Officer of Atsena Therapeutics, writes about the company's journey to the clinic for a challenging ocular gene therapy target. I have worked for nearly 20 years across academia and the biopharmaceutical industry to develop gene therapies for inherited retinal diseases. I met Sanford Boye, my other half in life and in science, in the lab. If you name… Read More

